Takeda Pharms Usa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TAKEDA PHARMS USA, and when can generic versions of TAKEDA PHARMS USA drugs launch?
TAKEDA PHARMS USA has forty approved drugs.
There are one hundred and six US patents protecting TAKEDA PHARMS USA drugs.
There are one thousand four hundred and twenty-seven patent family members on TAKEDA PHARMS USA drugs in fifty-nine countries and one hundred and eighty-eight supplementary protection certificates in nineteen countries.
Summary for Takeda Pharms Usa
International Patents: | 1427 |
US Patents: | 106 |
Tradenames: | 43 |
Ingredients: | 33 |
NDAs: | 40 |
Drugs and US Patents for Takeda Pharms Usa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-002 | Dec 14, 2012 | RX | Yes | Yes | 9,493,470 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-002 | Sep 30, 2013 | RX | Yes | No | 9,278,096*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Takeda Pharms Usa | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-003 | Oct 2, 2017 | RX | Yes | Yes | 9,611,283 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-001 | Dec 14, 2012 | RX | Yes | No | 9,029,533 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Takeda Pharms Usa | KAZANO | alogliptin benzoate; metformin hydrochloride | TABLET;ORAL | 203414-002 | Jan 25, 2013 | RX | Yes | Yes | 8,173,663 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Takeda Pharms Usa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Takeda Pharms Usa | MYDAYIS | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 022063-004 | Jun 20, 2017 | RE42096 | ⤷ Try a Trial |
Takeda Pharms Usa | VELCADE | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021602-001 | May 13, 2003 | 7,119,080 | ⤷ Try a Trial |
Takeda Pharms Usa | OSENI | alogliptin benzoate; pioglitazone hydrochloride | TABLET;ORAL | 022426-004 | Jan 25, 2013 | 6,329,404 | ⤷ Try a Trial |
Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-001 | Jul 15, 1999 | 6,211,205 | ⤷ Try a Trial |
Takeda Pharms Usa | INTUNIV | guanfacine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022037-003 | Sep 2, 2009 | 6,287,599*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TAKEDA PHARMS USA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Powder | 750 mg and 1000 mg | ➤ Subscribe | 2015-11-25 |
➤ Subscribe | Extended-release Tablets | 15 mg/1000 mg and 30 mg/1000 mg | ➤ Subscribe | 2011-09-23 |
➤ Subscribe | Tablets | 15 mg/500 mg and 15 mg/850 mg | ➤ Subscribe | 2008-03-06 |
➤ Subscribe | Delayed-release Pellets/Capsul | 15 mg and 30 mg | ➤ Subscribe | 2005-12-05 |
➤ Subscribe | Tablets | 30 mg/2 mg and 30 mg/4 mg | ➤ Subscribe | 2009-12-22 |
➤ Subscribe | Capsule | 60 mg | ➤ Subscribe | 2010-08-25 |
➤ Subscribe | Tablets | 6.25 mg, 12.5 mg and 25 mg | ➤ Subscribe | 2017-01-25 |
➤ Subscribe | Extended-release Capsules | 100 mg and 200 mg | ➤ Subscribe | 2006-02-02 |
➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mgand 20 mg | ➤ Subscribe | 2017-10-02 |
➤ Subscribe | Extended-release Capsules | 12.5 mg and 25 mg | ➤ Subscribe | 2017-08-07 |
➤ Subscribe | For Injection | 3.5 mg/vial | ➤ Subscribe | 2008-11-20 |
➤ Subscribe | Chewable Tablet | 500 mg, 750 mg and 1000 mg | ➤ Subscribe | 2008-10-27 |
➤ Subscribe | Delayed-release Tablets | 1.2 g | ➤ Subscribe | 2009-12-16 |
➤ Subscribe | Extended-release Tablets | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2009-12-29 |
➤ Subscribe | Tablets | 0.6 mg | ➤ Subscribe | 2011-12-23 |
➤ Subscribe | Delayed-release Orally Disinte | 15 mg and 30 mg | ➤ Subscribe | 2006-12-27 |
➤ Subscribe | Tablets | 12.5 mg/500 mg and 12.5 mg/1000 mg | ➤ Subscribe | 2017-01-25 |
➤ Subscribe | Delayed-release Capsule | 30 mg | ➤ Subscribe | 2010-11-30 |
➤ Subscribe | Tablets | 8 mg | ➤ Subscribe | 2009-07-22 |
➤ Subscribe | Extended-release Capsules | 37.5 mg and50 mg | ➤ Subscribe | 2017-08-03 |
➤ Subscribe | Tablets | 40 mg and 80 mg | ➤ Subscribe | 2013-02-13 |
➤ Subscribe | Capsules | 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg | ➤ Subscribe | 2011-02-23 |
➤ Subscribe | Injection | 10 mg/mL | ➤ Subscribe | 2015-08-25 |
International Patents for Takeda Pharms Usa Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Argentina | 048055 | ⤷ Try a Trial |
Australia | 2006232993 | ⤷ Try a Trial |
European Patent Office | 1749818 | ⤷ Try a Trial |
Singapore | 164281 | ⤷ Try a Trial |
Denmark | 2297115 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Takeda Pharms Usa Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0193256 | 2001C/011 | Belgium | ⤷ Try a Trial | PRODUCT NUMBER: PIOGLITAZONE; NAT. REGISTRATION NO/DATE: EU/1/001/150/001 20001018; FIRST REGISTRATION NO: CH 55378 01 20000927 |
1973545 | CA 2013 00066 | Denmark | ⤷ Try a Trial | PRODUCT NAME: POATINIB, HERUNDER PONATINIB HYDROCHLORID; REG. NO/DATE: EU/1/13/839/001-004 20130701 |
2300013 | 2019024 | Norway | ⤷ Try a Trial | PRODUCT NAME: BRIGATINIB ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/18/1264 20181218 |
2435024 | SPC/GB21/029 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, AND BUDESONIDE INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ES; REGISTERED: UK EU/1/20/1498 (NI) 20201210; UK PLGB 17901/0352-001 20201210 |
1261586 | 132012902044560 | Italy | ⤷ Try a Trial | PRODUCT NAME: SAXAGLIPTIN E METFORMINA(KOMBOGLYZE); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/11/731/001 A EU/1/11/731/014, 20111124 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.